Paper29416738
PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation.
Yin ZX and 14 others. Oncotarget, 2018. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation. Papers, record 29416738. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29416738
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA133053 | NCI NIH HHS | United States | R01CA133053 | PubMed | NIH RePORTER |
| R01 HL085324 | NHLBI NIH HHS | United States | R01HL085324 | PubMed and NIH | NIH RePORTER |
| R01 HL127338 | NHLBI NIH HHS | United States | R01HL127338 | PubMed and NIH | NIH RePORTER |
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27888811 | The role of p53 in cancer drug resistance and targeted chemotherapy. | Oncotarget | 2017 | https://conductscience.org/library/papers/27888811 | PubMed |
| 2 | 26975633 | APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. | Cancer Lett | 2016 | https://conductscience.org/library/papers/26975633 | PubMed |
| 3 | 16023595 | Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. | Cancer Cell | 2005 | https://conductscience.org/library/papers/16023595 | PubMed |
| 4 | 28254861 | Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. | Cancer Res | 2017 | https://conductscience.org/library/papers/28254861 | PubMed |
| 5 | 23035244 | Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2. | Proc Natl Acad Sci U S A | 2012 | https://conductscience.org/library/papers/23035244 | PubMed |
| 6 | 24857548 | Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. | Mol Cell | 2014 | https://conductscience.org/library/papers/24857548 | PubMed |
| 7 | 24406211 | The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. | Semin Cancer Biol | 2014 | https://conductscience.org/library/papers/24406211 | PubMed |
| 8 | 28087320 | Poly(ADP-ribose) polymerase activity and inhibition in cancer. | Semin Cell Dev Biol | 2017 | https://conductscience.org/library/papers/28087320 | PubMed |
| 9 | 15509775 | Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. | Mol Cell Biol | 2004 | https://conductscience.org/library/papers/15509775 | PubMed |
| 10 | 11875500 | Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Nat Med | 2002 | https://conductscience.org/library/papers/11875500 | PubMed |
| 11 | 26619122 | Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. | J Clin Invest | 2016 | https://conductscience.org/library/papers/26619122 | PubMed |
| 12 | 23355677 | Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/23355677 | PubMed |
| 13 | 27244886 | Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads. | Oncotarget | 2016 | https://conductscience.org/library/papers/27244886 | PubMed |
| 14 | 18094376 | TP53 mutations and survival in squamous-cell carcinoma of the head and neck. | N Engl J Med | 2007 | https://conductscience.org/library/papers/18094376 | PubMed |
| 15 | 26438158 | PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. | Mol Cancer Ther | 2015 | https://conductscience.org/library/papers/26438158 | PubMed |
| 16 | 28302823 | PARP inhibitors: Synthetic lethality in the clinic. | Science | 2017 | https://conductscience.org/library/papers/28302823 | PubMed |
| 17 | 21109480 | p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. | Oral Oncol | 2011 | https://conductscience.org/library/papers/21109480 | PubMed |
| 18 | 25263448 | LKB1 reduces ROS-mediated cell damage via activation of p38. | Oncogene | 2015 | https://conductscience.org/library/papers/25263448 | PubMed |
| 19 | 22982566 | Hypoxia, Mn-SOD and H(2)O(2) regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells. | Biochem Pharmacol | 2012 | https://conductscience.org/library/papers/22982566 | PubMed |
| 20 | 23847349 | Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets. | Cancer Discov | 2013 | https://conductscience.org/library/papers/23847349 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42939551 | Advances in p53 Therapies for Oral Squamous Cell Carcinoma: A Literature Review. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42939551 | PubMed |
| 39532848 | SNF2L maintains glutathione homeostasis by initiating SLC7A11 transcription through chromatin remodeling. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/39532848 | PubMed |
| 36978917 | Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers. | Antioxidants (Basel) | 2023 | https://conductscience.org/library/papers/36978917 | PubMed |
| 35269416 | Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53. | Cells | 2022 | https://conductscience.org/library/papers/35269416 | PubMed |
| 35204775 | APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells. | Biomolecules | 2022 | https://conductscience.org/library/papers/35204775 | PubMed |
| 35071005 | Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments. | Front Oncol | 2021 | https://conductscience.org/library/papers/35071005 | PubMed |
| 33470989 | p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors. | JCI Insight | 2021 | https://conductscience.org/library/papers/33470989 | PubMed |
| 32492656 | Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. | Aging (Albany NY) | 2020 | https://conductscience.org/library/papers/32492656 | PubMed |
| 31795418 | A Small Compound KJ-28d Enhances the Sensitivity of Non-Small Cell Lung Cancer to Radio- and Chemotherapy. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31795418 | PubMed |
| 31325708 | miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer. | Neoplasia | 2019 | https://conductscience.org/library/papers/31325708 | PubMed |
| 31178471 | Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide. | Neurol Med Chir (Tokyo) | 2019 | https://conductscience.org/library/papers/31178471 | PubMed |
| 30140002 | Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. | Sci Rep | 2018 | https://conductscience.org/library/papers/30140002 | PubMed |
Genes24
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29416738
GET https://conductscience.org/api/papers/v1/29416738/references?page=2